İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2023 · article

SPIOMET4HEALTH—efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial

Dergi Trials
ISSN1745-6215
YÖKSİS OpenAlex Açık erişim · gold
Yıl2023
Atıf10OpenAlex
Yüzdelik%86,6
FWCI2,011,00 = dünya ortalaması
Scopus (SJR)Q2
WoS (JCR)Q3

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıTRIALS
  • Katalog eşleşmesi (ISSN)Trials
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

OpenAlex İngilizce

BACKGROUND: Polycystic ovary syndrome (PCOS) is the most prevalent, chronic endocrine-metabolic disorder of adolescents and young women (AYAs), affecting 5-10% of AYAs worldwide. There is no approved pharmacological therapy for PCOS. Standard off-label treatment with oral contraceptives (OCs) reverts neither the underlying pathophysiology nor the associated co-morbidities. Pilot studies have generated new insights into the pathogenesis of PCOS, leading to the development of a new treatment consisting of a fixed, low-dose combination of two so-called insulin sensitisers [pioglitazone (PIO), metformin (MET)] and one mixed anti-androgen and anti-mineralocorticoid also acting as an activator of brown adipose tissue [spironolactone (SPI)], within a single tablet (SPIOMET). The present trial will evaluate the efficacy, tolerability and safety of SPIOMET, on top of lifestyle measures, for the treatment of PCOS in AYAs. METHODS: In this multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial, AYAs with PCOS will be recruited from 7 clinical centres across Europe. Intention is to randomise a total of 364 eligible patients into four arms (1:1:1:1): Placebo, PIO, SPI + PIO (SPIO) and SPI + PIO + MET (SPIOMET). Active treatment over 12 months will consist of lifestyle guidance plus the ingestion of one tablet daily (at dinner time); post-treatment follow-up will span 6 months. Primary endpoint is on- and post-treatment ovulation rate. Secondary endpoints are clinical features (hirsutism, menstrual regularity); endocrine-metabolic variables (androgens, lipids, insulin, inflammatory markers); epigenetic markers; imaging data (carotid intima-media thickness, body composition, abdominal fat partitioning, hepatic fat); safety profile; adherence, tolerability and acceptability of the medication; and quality of life in the study participants. Superiority (in this order) of SPIOMET, SPIO and PIO will be tested over placebo, and if present, subsequently the superiority of SPIOMET versus PIO, and if still present, finally versus SPIO. DISCUSSION: The present study will be the first to evaluate-in a randomised, double-blind, placebo-controlled way-the efficacy, tolerability and safety of SPIOMET treatment for early PCOS, on top of a lifestyle intervention. TRIAL REGISTRATION: EudraCT 2021-003177-58. Registered on 22 December 2021. https://www.clinicaltrialsregister.eu/ctr-search/search?query=%092021-003177-58 .

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

10atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yazarlar

27
  1. Cristina Garcia-Beltran 1
  2. Rita Malpique 2
  3. Marianna S. Andersen 3
  4. FİRDEVS BAŞ İSTANBUL ÜNİVERSİTESİ 4
  5. Judit Bassols 5
  6. FATMA FEYZA DARENDELİLER 6
  7. Marta Diaz 7
  8. Marta Dieris 8
  9. Flaminia Fanelli 9
  10. Elke Fröhlich 10
  11. Alessandra Gambineri 11
  12. Dorte Glintberg 12
  13. Abel Lope-Bermejo 13
  14. Christoper Mann 14
  15. Silvia Marin 15
  16. Barbara Obenmayer-Pietsch 16
  17. Ronnary Odegard 17
  18. Pernille Ravn 18
  19. Thomas Reinehr 19
  20. Matteo Renzulli 20
  21. Cristina Salvador 21
  22. Viole Singer 22
  23. Ester Vanky 23
  24. Juan Vicente Torres 24
  25. MELEK YILDIZ 25
  26. Francis De Zegher 26
  27. Lourdez İbanez 27